Home/Pipeline/Multiple Unnamed TCR-T Candidates

Multiple Unnamed TCR-T Candidates

Solid Tumors

PreclinicalIn Development

Key Facts

Indication

Solid Tumors

Phase

Preclinical

Status

In Development

Company

TScan Therapeutics

About TScan Therapeutics

TScan Therapeutics is a fully integrated, clinical-stage biotech focused on unleashing the immune system through TCR-T cell therapies. Founded in 2018, the company's lead program, TSC-101, is in a Phase 1 trial for AML and MDS, and it has a pipeline of candidates for solid tumors and autoimmune disorders. TScan differentiates itself with a proprietary platform for target discovery and is advancing both ex vivo and in vivo engineered T cell approaches.

View full company profile

Therapeutic Areas

Oncology Autoimmune Diseases

Other Solid Tumors Drugs

Drug	Company	Phase	Status
GSK4362676	GSK plc	Phase 1	Active
ABBV-154	AbbVie	Phase 1	Active
TAK-981	Takeda Pharmaceutical	Phase 1/2	Active
TAK-676	Takeda Pharmaceutical	Phase 1	Active
TAK-573	Takeda Pharmaceutical	Phase 1	Active
TAK-164	Takeda Pharmaceutical	Phase 1	Active
SHR-1316	Jiangsu Hengrui Medicine	Phase 1/2	Active
BAY 2927088	Bayer	Phase 1	Active
ASP1929	Astellas Pharma	Phase 2	Active
IBI188	Innovent Biologics	Phase 1	Active
Bispecific Antibody	Akeso	Phase 1/2	Active
CSPC-DM02	CSPC Pharmaceutical Group Limited	Phase 2	Active